Department of General Surgery, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China.
Department of General Surgery, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China.
Biochem Pharmacol. 2023 Oct;216:115752. doi: 10.1016/j.bcp.2023.115752. Epub 2023 Aug 25.
This study aimed to investigate the protective effects of S-adenosylmethionine (SAM) on irinotecan-induced intestinal barrier dysfunction and microbial ecological dysregulation in both mice and human colon cell line Caco-2, which is widely used for studying intestinal epithelial barrier function. Specifically, this study utilized Caco-2 monolayers incubated with 7-ethyl-10-hydroxycamptothecin (SN-38) as well as an irinotecan-induced diarrhea model in mice. Our study found that SAM pretreatment significantly reduced body weight loss and diarrhea induced by irinotecan in mice. Furthermore, SAM inhibited the increase of intestinal permeability in irinotecan-treated mice and ameliorated the decrease of Zonula occludens-1(ZO-1), Occludin, and Claudin-1 expression. Additionally, irinotecan treatment increased the relative abundance of Proteobacteria compared to the control group, an effect that was reversed by SAM administration. In Caco-2 monolayers, SAM reduced the expression of reactive oxygen species (ROS) and ameliorated the decrease in transepithelial electrical resistance (TER) and increase in fluorescein isothiocyanate-dextran 4000 Da (FD-4) flux caused by SN-38. Moreover, SAM attenuated changes in the localization and distribution of ZO-1and Occludin in Caco-2 monolayers induced by SN-38 and protected barrier function by inhibiting activation of the p38 MAPK/p65 NF-κB/MLCK/MLC signaling pathway. These findings provide preliminary evidence for the potential use of SAM in treating diarrhea caused by irinotecan.
本研究旨在探讨 S-腺苷甲硫氨酸(SAM)对伊立替康诱导的肠道屏障功能障碍和微生物生态失调的保护作用,分别在小鼠和人结肠细胞系 Caco-2 中进行研究,后者广泛用于研究肠道上皮屏障功能。具体而言,本研究利用 Caco-2 单层细胞培养物孵育 7-乙基-10-羟基喜树碱(SN-38)以及伊立替康诱导的小鼠腹泻模型。我们的研究发现,SAM 预处理可显著减轻伊立替康诱导的小鼠体重减轻和腹泻。此外,SAM 抑制了伊立替康治疗小鼠的肠道通透性增加,并改善了 Zonula occludens-1(ZO-1)、Occludin 和 Claudin-1 表达的降低。此外,与对照组相比,伊立替康治疗增加了变形菌门的相对丰度,而 SAM 给药可逆转这种作用。在 Caco-2 单层细胞中,SAM 降低了活性氧(ROS)的表达,并改善了 SN-38 引起的跨上皮电阻(TER)降低和荧光素异硫氰酸酯-右旋糖酐 4000(FD-4)通量增加。此外,SAM 减轻了 SN-38 诱导的 Caco-2 单层细胞中 ZO-1 和 Occludin 定位和分布的变化,并通过抑制 p38 MAPK/p65 NF-κB/MLCK/MLC 信号通路的激活来保护屏障功能。这些发现为 SAM 治疗伊立替康引起的腹泻提供了初步证据。